Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 229-234

  Doudican, Nicole A ^a   Bowling, Benjamin ^a   Orlow, Seth J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic trioxide; Erysolin; Leukemia; Reactive oxygen species; Sulforaphane

Indexed keywords

ACETYLCYSTEINE; ARSENIC TRIOXIDE; ERUCIN; ERYSOLIN; GLUTATHIONE; ISOTHIOCYANIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL LEVEL; CELL TYPE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG STRUCTURE; FOOD DRUG INTERACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; VEGETABLE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CELL DEATH; DRUG SYNERGISM; HUMANS; ISOTHIOCYANATES; LEUKEMIA; OXIDES; REACTIVE OXYGEN SPECIES; SULFIDES; SULFONES; THIOCYANATES; TUMOR CELLS, CULTURED; VEGETABLES;

EID: 74849140129     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.017     Document Type: Article

References (35)

1. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6 Suppl 2 (2001) 1-2
2. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 Suppl 2 (2001) 11-16
3. Verstovsek S., Giles F., Quintas-Cardama A., Perez N., Ravandi-Kashani F., Beran M., et al. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?. Hematol Oncol 24 (2006) 181-188
4. Ling Y.H., Jiang J.D., Holland J.F., and Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 62 (2002) 529-538
5. Fox E., Razzouk B.I., Widemann B.C., Xiao S., O'Brien M., Goodspeed W., et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111 (2008) 566-573
6. Cohen J.H., Kristal A.R., and Stanford J.L. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92 (2000) 61-68
7. Zhang Y., and Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 54 (1994) 1976s-1981s
8. Brooks J.D., Paton V.G., and Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 10 (2001) 949-954
9. Gamet-Payrastre L., Li P., Lumeau S., Cassar G., Dupont M.A., Chevolleau S., et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60 (2000) 1426-1433
10. Fimognari C., Nusse M., Cesari R., Iori R., Cantelli-Forti G., and Hrelia P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23 (2002) 581-586
11. Chou T.C., and Talalay P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252 (1977) 6438-6442
12. Chou T.C., and Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4 (1983) 450-454
13. Bowling B.D., Doudican N., Manga P., and Orlow S.J. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother Pharmacol 63 (2008) 37-43
14. Ye L., Dinkova-Kostova A.T., Wade K.L., Zhang Y., Shapiro T.A., and Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 316 (2002) 43-53
15. Clarke J.D., Dashwood R.H., and Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269 (2008) 291-304
16. Chen Y.C., Lin-Shiau S.Y., and Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 177 (1998) 324-333
17. Singh S.V., Srivastava S.K., Choi S., Lew K.L., Antosiewicz J., Xiao D., et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 280 (2005) 19911-19924
18. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
19. Yang C.H., Kuo M.L., Chen J.C., and Chen Y.C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81 (1999) 796-799
20. Wang L.I., Giovannucci E.L., Hunter D., Neuberg D., Su L., and Christiani D.C. Dietary intake of Cruciferous vegetables, Glutathione S-transferase (GST) polymorphisms and lung cancer risk in a Caucasian population. Cancer Causes Control 15 (2004) 977-985
21. Lunghi P., Tabilio A., Lo-Coco F., Pelicci P.G., and Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 19 (2005) 234-244
22. Li L., Wang J., Ye R.D., Shi G., Jin H., Tang X., et al. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol 217 (2008) 486-493
23. Ralph S.J. Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs 2008 (2008) 260146
24. Kim H., Kim E.H., Eom Y.W., Kim W.H., Kwon T.K., Lee S.J., et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 66 (2006) 1740-1750
25. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 60 (2000) 3065-3071
26. Porter A.C., and Fanger G.R. Vaillancourt RR: signal transduction pathways regulated by arsenate and arsenite. Oncogene 18 (1999) 7794-7802
27. Choi W.Y., Choi B.T., Lee W.H., and Choi Y.H. Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells. Biomed Pharmacother 62 (2008) 637-644
28. Jakubikova J., Sedlak J., Mithen R., and Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 69 (2005) 1543-1552
29. Jakubikova J., Bao Y., and Sedlak J. Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines. Anticancer Res 25 (2005) 3375-3386
30. Juge N., Mithen R.F., and Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64 (2007) 1105-1127
31. Zhang Y., Tang L., and Gonzalez V. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther 2 (2003) 1045-1052
32. 3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 105 (2005) 1198-1203
33. Chang J., Voorhees P., Kolesar J., Ahuja H., Sanchez F., Rodriguez G., et al. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol (2008)
34. Davison K., Cote S., Mader S., and Miller W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17 (2003) 931-940
35. Hu R., Hebbar V., Kim B.R., Chen C., Winnik B., Buckley B., et al. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther 310 (2004) 263-271